Skip to content

Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin

Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00842374
Enrollment
32
Registered
2009-02-12
Start date
2008-12-31
Completion date
2012-12-31
Last updated
2013-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-STEMI Acute Coronary Syndrome

Brief summary

This is a registry of patients with non ST segment elevation Myocardial Infarction (heart attack) and/or unstable acute coronary artery syndrome treated with a standardized protocol including Bivalirudin. Data will be collected on diagnosis, treatment and outcomes.

Interventions

None listed

Sponsors

The Medicines Company
CollaboratorINDUSTRY
Minneapolis Heart Institute Foundation
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 * Chest pain or symptoms believed to be an anginal equivalent and representing myocardial ischemia, lasting at least 10 minutes within the past 24 hours * Having any one of the following: 1. Ischemic changes on ECG: ST depression \>0.5 mm OR T wave inversion \>2 mm 2. Positive cardiac markers 3. New onset CHF presumed secondary to ischemia 4. Pulmonary edema 5. Known coronary artery disease with typical symptoms 6. Hemodynamic instability 7. Sustained ventricular tachycardia

Exclusion criteria

* For the purpose of the SSDI, patients will be excluded if we are unable to obtain their Social Security Number.

Design outcomes

Primary

MeasureTime frame
Incidence of MACE defined as any one of the following: • Acute myocardial infarction/reinfarction • Ischemia-driven unplanned revascularizations • Stroke • All cause Mortality30 days

Secondary

MeasureTime frame
Rehospitalization for ACS30 days
All cause mortality30 days, one year and up to 5 years
Major Bleedingin hospital and at 30 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026